Cas:1089282-52-9 1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene manufacturer & supplier

Chemical Name:1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene

CAS.NO:1089282-52-9

Synonyms:1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene

Molecular Formula:C₉H₁₀FNO₃

Molecular Weight:199.17900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:55.05000

Exact Mass:199.06400

LogP:2.82810

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene Use and application,1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene technical grade,usp/ep/jp grade.

Related News: Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. 1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene manufacturer A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene supplier Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. 1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene vendor But they’ll be subject to up to 14 days of mandatory quarantine once they’re back in the US. 1-Ethyl-2-fluoro-4-methoxy-5-nitrobenzene factory A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting.